NCCN Recommends Zanubrutinib as First-Line, Se... - CLL Support
NCCN Recommends Zanubrutinib as First-Line, Second-Line Therapy in CLL, SLL
You need to be a member of this community to see this post.
Read more about...
36 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Zanubrutinib-Gazyva Shows Promise for CLL/SLL
June 25, 2019
Zanubrutinib (BGB-3111) is an investigational small molecule inhibitor of Bruton’s...
Zanubrutinib looks promising on all fronts in first interim analysis of ALPINE Trial - Ibrutinib v Zanubrutinib in R/R CLL - report from EHA
Dr Pete Hillmen (UK) reported on this at EHA on 11th June 2021
Background
First-generation BTK...
YABTKi or Yet Another BTK inhibitor - an A to Z list of Bruton's Tyrosine Kinase Inhibitors and Degraders following ibrutinib's success
I'll admit that YABTKi is not a recognised CLL related acronym, (acronym lists are here...
Optimal Treatment Combinations in the Management of CLL/SLL Jeff Sharman, MD Provided by Clinical Care Options, LLC
Optimal Treatment Combinations in the Management of CLL/SLL Jeff Sharman, MD
An installment...
Zanubrutinib PFS, ORR Is Superior to Ibrutinib for Relapsed/Refractory CLL/SLL
Zanubrutinib PFS (Progression Free Survival) , ORR (Overall Response Rate) Is Superior to...
Related Posts
- Advances in Targeted Therapy for R/R CLL OncLive videos & transcripts by Nirav Shah MD & Nicole Lamanna MD
- Efficacy and safety of new‑generation BTKis (primarily acalabrutinib and zanubrutinib) in CLL/SLL: a systematic review and meta‑analysis
BTK inhibitors for the treatment of CLL - the current state of play of 'brutinibs'- FDA Approves Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphom
- Ibrutinib combinations in CLL therapy: scientific rationale and clinical results
